Skip to content
CompoundSci
All peptides
Research vial labelled GLOW (GHK-Cu + BPC-157 + TB-500), a Skin and cosmetic peptide studied in preclinical and clinical literature

GLOW (GHK-Cu + BPC-157 + TB-500)

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Copper complexes are not chemically neutral partners in a shared vial. Stability of these blends is undocumented.

General profile

Class
Skin and cosmetic
Evidence
Early or preclinical only
Studied dose range
Per component, blend labelling varies
Frequency in protocols
Daily
Route
Subcutaneous
Half life
Mixed
Reconstitution
3 mL bacteriostatic water per blended vial
Storage
Refrigerated, light-protected, ~30 days

Timing and cycling in the literature

Usually dosed in the evening window

Daily

Skin remodelling work is dosed at night alongside repair cycles. The copper component should never share a barrel with anything else.

Reported cycle: 8 weeks on, 4 weeks off

Paced to the GHK-Cu skin remodelling window, which is the slowest component.

Watch for: Taste changes and fatigue, both early signs of copper excess.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    GLOW (GHK-Cu + BPC-157 + TB-500) + The window right after cardiac surgery

    Not alongside an active cardiac recovery regimen

    Bleeding risk and the cardiac drug regimen come first. Pro-angiogenic and vasodilatory compounds can clash with that care. Physician territory, not a timing problem.

  • Hard stopBody level hard stop

    GLOW (GHK-Cu + BPC-157 + TB-500) + Active cancer, pregnancy or heavy immunosuppression

    Absolute stop with an active cancer history

    Angiogenesis is the whole mechanism people are chasing here, and it acts everywhere in the body, not only in the tendon you care about. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference.

  • Hard stopTiming

    GLOW (GHK-Cu + BPC-157 + TB-500) + GHK-Cu

    Duplicate copper exposure

    GLOW is built around GHK-Cu. Adding standalone GHK-Cu on top pushes copper intake past anything described and copper is cumulative.

  • Hard stopTiming

    GLOW (GHK-Cu + BPC-157 + TB-500) + KLOW (GLOW + KPV)

    KLOW already contains GLOW

    KLOW is the same three compounds plus KPV. Running both is a straight duplicate of every shared ingredient.

  • Pick oneRedundant, pick one

    GLOW (GHK-Cu + BPC-157 + TB-500) + KLOW (GLOW + KPV)

    Same target hit twice

    KLOW is GLOW plus KPV. Same base blend twice.

  • Pick oneRedundant, pick one

    GLOW (GHK-Cu + BPC-157 + TB-500) + GHK-Cu

    Same target hit twice

    GLOW already carries the GHK-Cu portion.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how GLOW (GHK-Cu + BPC-157 + TB-500) fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Search the full literature